Overview
REGN market data
Price History
REGN price chart · 1M
- O
- 828.42
- H
- 829.39
- L
- 814.78
- C
- 814.96
- Vol
- 16,513.00
- Source
- US equities market feed
- Observed
- Aug 26, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $828.42
- Previous Close
- $833.98
- Day High
- $829.39
- Day Low
- $814.78
- 52 Week High
- $846.52
- 52 Week Low
- $590.96
- 7 Day Return
- -3.09%
- 30 Day Return
- +22.32%
- 90 Day Return
- +31.29%
- 1 Year Return
- +7.57%
- Daily Notional Volume
- $13.5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 18.98 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $41.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.5% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 27.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $541.00 – $847.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $82.2B · P/B 2.60 · P/S 5.29.
Company News
IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?The Motley Fool · Aug 21, 2026, 12:15 PM
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder DrugBenzinga · Aug 20, 2026, 1:25 PM
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain HemorrhageBenzinga · Aug 20, 2026, 11:25 AM
Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans ProgressivaBenzinga · Aug 19, 2026, 6:02 PM
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent IndicationBenzinga · Aug 18, 2026, 2:46 PM
Big Pharma's Future Growth Rests on Chinese Science? Expert Says: 'We Can't Ban Our Way Out of This'Benzinga · Aug 13, 2026, 2:41 AM
LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell CarcinomaBenzinga · Aug 6, 2026, 3:35 PM
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit – Hagens BermanGlobenewswire Inc · Aug 6, 2026, 11:15 AM
REGN ALERT: Hagens Berman Alerts Regeneron Pharmaceuticals, Inc. (REGN) Investors to Pending Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate FailureGlobenewswire Inc · Aug 4, 2026, 11:00 AM
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740Benzinga · Aug 3, 2026, 6:43 PM